Fate Therapeutics (FATE) Competitors $1.12 -0.02 (-1.75%) Closing price 04:00 PM EasternExtended Trading$1.15 +0.03 (+2.59%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. TYRA, BCAX, KURA, TSHA, MNMD, ABVX, VALN, ZVRA, BCYC, and SEPNShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Tyra Biosciences (TYRA), Bicara Therapeutics (BCAX), Kura Oncology (KURA), Taysha Gene Therapies (TSHA), Mind Medicine (MindMed) (MNMD), Abivax (ABVX), Valneva (VALN), Zevra Therapeutics (ZVRA), Bicycle Therapeutics (BCYC), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Tyra Biosciences Bicara Therapeutics Kura Oncology Taysha Gene Therapies Mind Medicine (MindMed) Abivax Valneva Zevra Therapeutics Bicycle Therapeutics Septerna Tyra Biosciences (NASDAQ:TYRA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Is TYRA or FATE more profitable? Tyra Biosciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Tyra Biosciences' return on equity of -26.90% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tyra BiosciencesN/A -26.90% -25.54% Fate Therapeutics -1,318.93%-47.17%-34.60% Do institutionals & insiders believe in TYRA or FATE? 84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 15.2% of Tyra Biosciences shares are owned by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, TYRA or FATE? Tyra Biosciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Do analysts rate TYRA or FATE? Tyra Biosciences presently has a consensus target price of $30.83, indicating a potential upside of 206.80%. Fate Therapeutics has a consensus target price of $3.83, indicating a potential upside of 242.26%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Tyra Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has higher earnings & valuation, TYRA or FATE? Tyra Biosciences has higher earnings, but lower revenue than Fate Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTyra BiosciencesN/AN/A-$86.48M-$1.63-6.17Fate Therapeutics$13.63M9.42-$186.26M-$1.49-0.75 Does the media refer more to TYRA or FATE? In the previous week, Tyra Biosciences had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 5 mentions for Tyra Biosciences and 2 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.65 beat Tyra Biosciences' score of 0.17 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTyra Biosciences beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.65M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.13%P/E RatioN/A21.3126.2119.90Price / Sales9.42241.40405.84161.31Price / CashN/A41.8936.4957.06Price / Book0.407.518.055.38Net Income-$186.26M-$55.05M$3.15B$248.50M7 Day Performance-3.45%2.45%1.85%2.97%1 Month Performance-13.85%7.33%4.81%6.02%1 Year Performance-65.22%5.38%34.86%20.39% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.0881 of 5 stars$1.12-1.8%$3.83+242.3%-65.0%$130.65M$13.63M0.00550Gap DownTYRATyra Biosciences1.9387 of 5 stars$9.57+5.2%$30.83+222.2%-43.8%$508.07MN/A-5.8720News CoverageAnalyst ForecastBCAXBicara TherapeuticsN/A$9.29+6.7%$31.86+242.9%N/A$506.68MN/A0.0032KURAKura Oncology4.5523 of 5 stars$5.77+1.8%$24.50+324.6%-73.6%$499.54M$67.99M-2.75130TSHATaysha Gene Therapies3.3687 of 5 stars$2.31-2.9%$8.00+246.3%+3.5%$495.87M$8.33M-6.79180Analyst ForecastMNMDMind Medicine (MindMed)2.4934 of 5 stars$6.49-0.9%$25.50+292.9%-5.5%$490.32MN/A-5.0340ABVXAbivax2.4613 of 5 stars$7.65+3.4%$31.00+305.2%-43.5%$485.39MN/A0.0061Positive NewsHigh Trading VolumeVALNValneva1.9978 of 5 stars$5.67-2.2%$15.50+173.4%-19.0%$482.46M$183.52M-4.76700Positive NewsZVRAZevra Therapeutics2.4087 of 5 stars$8.81-2.1%$22.29+153.0%+98.4%$481.73M$23.61M-4.6420Analyst ForecastGap UpBCYCBicycle Therapeutics3.8165 of 5 stars$6.95-4.0%$25.00+259.7%-65.4%$481.29M$35.28M-2.21240News CoverageSEPNSepterna1.7057 of 5 stars$10.57+0.6%$26.75+153.1%N/A$471.00M$1.08M0.00N/APositive News Related Companies and Tools Related Companies Tyra Biosciences Alternatives Bicara Therapeutics Alternatives Kura Oncology Alternatives Taysha Gene Therapies Alternatives Mind Medicine (MindMed) Alternatives Abivax Alternatives Valneva Alternatives Zevra Therapeutics Alternatives Bicycle Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts